COCHLEAR LIMITED — Regulatory Filings 2008

Feb 21, 2008

==> picture [595 x 55] intentionally omitted <==

==> picture [595 x 54] intentionally omitted <==

ASX / MEDIA RELEASE 22 February 2008

COCHLEAR TO WORK WITH FDA TO RESOLVE OUTSTANDING ISSUES IN WARNING LETTER

SYDNEY: 22 February 2008

On 12 February 2008, Cochlear Limited (COH.AX) advised that it may receive a warning letter from the United States Food and Drug Administration (FDA). Cochlear Bone Anchored Solutions AB (BAS), Cochlear's Swedish subsidiary, has now received a warning letter from the FDA.

Cochlear is committed to full compliance with FDA regulations and will work with the FDA to swiftly resolve the outstanding issues.

The warning letter advises that an import alert has been issued relating to the import of Baha® products from Sweden into the USA. Inventory received into the USA prior to the import alert becoming effective can continue to be distributed. Cochlear believes that inventory already in the USA will meet customer and patient demands for the immediate future.

Contacts: Dr Chris Roberts, CEO/President Ph: (02) 9428 6555

Neville Mitchell, CFO Ph: (02) 9428 6555

==> picture [363 x 114] intentionally omitted <==

ASX Announcement / Media Release 22 February 2008

Page 1 of 1